Infections

All Conditions

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Neoplasms

Mouth and Tooth Diseases

Rare Diseases

Communicable Diseases

Virus Diseases

Papillomavirus Infections

Papilloma

Measles

Rubella

Mumps

Escherichia coli Infections

Disease Attributes

Neoplasms, Squamous Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Paramyxoviridae Infections

Mononegavirales Infections

RNA Virus Infections

Togaviridae Infections

Parotitis

Parotid Diseases

Salivary Gland Diseases

Mouth Diseases

Stomatognathic Diseases

Sexually Transmitted Diseases

Sexually Transmitted Diseases, Viral

DNA Virus Infections

Tumor Virus Infections

Genital Diseases

Urogenital Diseases

All Drugs and Chemicals

Vaccines

Participants in this arm will be simultaneously administrated with one dose of HPV 16/18 bivalent vaccine and one dose of MMR vaccine. six month later, they are going to receive a second dose of HPV 16/18 bivalent vaccine.

Participants in this arm will be receieve HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months) first. After finished HPV vaccination, they are going to receive MMR vaccine at the 7th month.

Participants in this arm will be receieve MMR vaccine first. One month later, they are going to receieve HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months)

Simultaneously administrated with MMR vaccine and HPV 16/18 bivalent vaccine at first. And six months later, administrated with the second dose of HPV 16/18 bivalent vaccine.

HPV+MMR（0d），HPV（6m）

Administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months).And at the 7th month , administrated with MMR vaccine.

HPV（0d），HPV（6m），MMR（7m）

Administrated with MMR vaccine at first day. And administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months).

MMR（0d），HPV（1m），HPV（7m）

The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles Mumps and Rubella Combined Vaccine, Live（MMR）

Main subjects:

To evaluate the immunogenicity of HPV vaccine and MMR vaccine at the same time but at different sites as not inferior to vaccination of HPV vaccine or MMR vaccine alone.

Secondary subjects:

To evaluate the safety of simultaneous administration of HPV vaccine and MMR vaccine.

The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine

Immunogenicity and Safety of Concomitant Inoculation of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia Coli) and Measles Mumps and Rubella Combined Vaccine, Live

Detect the level of anti-HPV 16 and 18 specific neutralizing antibodies at one month after the second dose to determine whether group A is non-inferior to group B

Detect the level of anti-measles specific neutralizing antibodies at one month after MMR vaccination to determine whether group A is non-inferior to group C

Detect the level of anti-rubella specific neutralizing antibodies at one month after MMR vaccination to determine whether group A is non-inferior to group C

Detect the level of anti-mumps specific neutralizing antibodies at one month after MMR vaccination to determine whether group A is non-inferior to group C

Adverse reactions associated with vaccine will be observed in subjects after vaccination. To evaluate number of adverse events/reactions compared with non-simultane vaccination group.

To evaluate number of adverse events/reactions compared with non-simultane vaccination group.

safety analysis. To evaluate number of SAEs compared with the non-simultane vaccination group.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine	NCT05279248	Human Papilloma... Human Papilloma... Measles Rubella Mumps	HPV+MMR（0d），HPV... HPV（0d），HPV（6m）... MMR（0d），HPV（1m）...	13 Years - 14 Years	Zhejiang Provincial Center for Disease Control and Prevention
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine	NCT05279248	Human Papilloma... Human Papilloma... Measles Rubella Mumps	HPV+MMR（0d），HPV... HPV（0d），HPV（6m）... MMR（0d），HPV（1m）...	13 Years - 14 Years	Zhejiang Provincial Center for Disease Control and Prevention

Spots Global Cancer Trial Database for hpv+mmr（0d），hpv（6m）